Evidence map›Paper›PMID 19735878›Full record

ArticleInternational journal of radiation oncology, biology, physics2009

Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity.

Santosh K Sandur, Amit Deorukhkar, Manoj K Pandey, Ana María Pabón, Shujun Shentu, Sushovan Guha, Bharat B Aggarwal, Sunil Krishnan

Registry-linked trialAbstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07248020 (A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer), which is not on this map. Cited by 91 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07248020 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue

TypeinterventionalSponsorChang Gung Memorial HospitalRan2026 to 2028Enrolled72ConditionsRectal Cancer, Locally Advanced Rectal Cancer, Radiation-Induced Enteritis, Radiation ProctitisArmsCurcumin (BCM-95®)
3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia.Cancer prevention research (Philadelphia, Pa.) · 2011
    Trial
  3. Review
  4. Article
  5. Article
  6. [Curcumin-loaded nanoparticles reversed radiotherapy-triggered enhancement of MDR1 expression of CNE-2 cells in nasopharyngeal carcinoma].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2025
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Iron metabolism in colorectal cancer: a balancing act.Cellular oncology (Dordrecht, Netherlands) · 2023
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Identification ofMolecules (Basel, Switzerland) · 2022
    Article
  17. Review
  18. Review
  19. Article
  20. Review

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Santosh K SandurDepartment of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA.
Amit Deorukhkar
Manoj K Pandey
Ana María Pabón
Shujun Shentu
Sushovan Guha
Bharat B Aggarwal
Sunil Krishnan

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

purposeRadiation therapy is an integral part of the preoperative treatment of rectal cancers. However, only a minority of patients achieve a complete pathologic response to therapy because of resistance of these tumors to radiation therapy. This resistance may be mediated by constitutively active pro-survival signaling pathways or by inducible/acquired mechanisms in response to radiation therapy. Simultaneous inhibition of these pathways can sensitize these tumors to radiation therapy. METHODS AND MATERIALS: Human colorectal cancer cells were exposed to clinically relevant doses of gamma rays, and the mechanism of their radioresistance was investigated. We characterized the transcription factor nuclear factor-kappaB (NF-kappaB) activation as a mechanism of inducible radioresistance in colorectal cancer and used curcumin, the active ingredient in the yellow spice turmeric, to overcome this resistance.

resultsCurcumin inhibited the proliferation and the post-irradiation clonogenic survival of multiple colorectal cancer cell lines. Radiation stimulated NF-kappaB activity in a dose- and time-dependent manner, whereas curcumin suppressed this radiation-induced NF-kappaB activation via inhibition of radiation-induced phosphorylation and degradation of inhibitor of kappaB alpha, inhibition of inhibitor of kappaB kinase activity, and inhibition of Akt phosphorylation. Curcumin also suppressed NF-kappaB-regulated gene products (Bcl-2, Bcl-x(L), inhibitor of apoptosis protein-2, cyclooxygenase-2, and cyclin D1).

conclusionsOur results suggest that transient inducible NF-kappaB activation provides a prosurvival response to radiation that may account for development of radioresistance. Curcumin blocks this signaling pathway and potentiates the antitumor effects of radiation therapy.

Indexed as

ApoptosisCell Line, TumorCell ProliferationColonic NeoplasmsColorectal NeoplasmsCurcuminDose-Response Relationship, DrugEnzyme InhibitorsGene Expression RegulationHT29 CellsHumansNeoplasm ProteinsNF-kappa BPhosphorylationProto-Oncogene Proteins c-aktRadiation-Sensitizing AgentsCurcuminEnzyme InhibitorsNeoplasm ProteinsNF-kappa BProto-Oncogene Proteins c-aktRadiation-Sensitizing Agents

Identifiers

PMID19735878
PMCPMC3090721

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.